Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.53 |
| ▸ | ITK | Q08881 | 12/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 3/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142647 | 0.91 | CHEK1 (0.52) | CHEK1ITKTRPA1MAP2K4CDK7 | |
| SCHEMBL146941 | 0.91 | CHEK1 (0.54) | CHEK1ITKTRPA1MAP2K4 | |
| SCHEMBL5635710 | 0.82 | CHEK1 (0.54) | CHEK1ITK | |
| SCHEMBL147603 | 0.81 | ITK (0.66) | CHEK1ITKTRPA1MAP2K4 | |
| SCHEMBL143964 | 0.81 | ITK (0.70) | CHEK1ITKTRPA1 | |
| SCHEMBL5636233 | 0.81 | ITK (0.53) | CHEK1ITKMAP2K4 | |
| SCHEMBL144764 | 0.80 | MAP2K4 (0.65) | CHEK1ITKTRPA1MAP2K4CDK7 | |
| SCHEMBL142590 | 0.79 | ITK (0.73) | CHEK1ITK | |
| SCHEMBL145284 | 0.77 | MAP2K4 (0.43) | CHEK1ITKMAP2K4 | |
| SCHEMBL5662556 | 0.77 | CHEK1 (0.57) | CHEK1ITKTRPA1MAP2K4CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | CHEK1 499/4885ITK 377/4885TRPA1 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.